ArticleBMC psychiatry2026
Magnetic seizure therapy for major depressive disorder: age-related differences in efficacy and cognitive side effects.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Insular spontaneous activity changes after dialectical behavior therapy skills training for depressed patients with non-suicidal self-injury: a randomized controlled trial.BMC psychiatry · 2026Trial
- Comparative efficacy and cognitive function of magnetic seizure therapy and electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMajor depressive disorder (MDD) is a prevalent mental health condition affecting both adolescents and adults, yet age-specific differences in treatment response remain underexplored. Magnetic Seizure Therapy (MST) is an emerging neuromodulation technique for treatment-resistant depression. This study aimed to compare the efficacy, tolerability, and cognitive effects of MST between adolescents and adults with MDD.
methodsThis single-center prospective study enrolled 128 patients with MDD, including 67 adolescents and 61 adults. All participants received MST and were assessed at baseline, 72 h, and 3 months post-treatment. Clinical outcomes were evaluated using HAMD-17, HAMA, BPRS, MoCA, C-SSRS, and CGI. Group differences in treatment response, cognitive outcomes, and tolerability were analyzed over time.
resultsAt 72 h post-treatment, adolescents had significantly lower HAMD-17 and HAMA scores (all p < 0.001) than adults, indicating faster initial improvement. By 3 months, adults reached similar symptom levels. C-SSRS decreased more in adults (p = 0.001). Analysis of MoCA subscales at 72 h revealed greater declines in delayed recall and executive function in adults, with no significant changes in adolescents (p = 0.038 and 0.039, respectively), whereas no differences were observed at 3 months. Common adverse events in adults included headache, memory decline, fatigue, and vital sign abnormalities, all less frequent in adolescents (p < 0.05); myalgia occurred only in adolescents, while dizziness and nausea/vomiting showed no group differences.
conclusionMST is effective in both groups, but adolescents demonstrate faster response, better cognitive preservation, and fewer somatic side effects, supporting its use in younger patients. REGISTRY NAME: Magnetic Seizure Therapy and modified electroconvulsive therapy for the efficacy and impact on cognitive function in adolescents with treatment-resistant depression. REGISTRATION NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.